A Phase III, Randomized, Controlled, Open-label, Multicenter, Global Study of Capmatinib Versus SoC Docetaxel Chemotherapy in Previously Treated Patients With EGFR wt, ALK Negative, Locally Advanced or Metastatic (Stage IIIB/IIIC or IV) NSCLC Harboring MET Exon 14 Skipping Mutation (METΔex14)
Latest Information Update: 05 Feb 2025
At a glance
- Drugs Capmatinib (Primary) ; Docetaxel
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms GeoMETry-III
- Sponsors Novartis; Novartis Pharmaceuticals
- 16 May 2024 This trial has been completed in Lithuania (End date: 2023-11-06) according to European Clinical Trials Database record.
- 05 Apr 2024 This study has been completed in Portugal, according European Clinical Trials Database record.
- 13 Dec 2023 This study has been completed in France, according European Clinical Trials Database record.